News
FRNM
16.31
-3.49%
-0.59
Biotech Stocks At 52-Week Highs - OABI +13%, FRNM, EXEL, FTH, LFST
NASDAQ · 4d ago
Elevance update guidelines cover Freenome CRC test, says Guggenheim
TipRanks · 6d ago
Cathie Wood's Ark weekly recap: Ark Invest boosts NVDA, AVGO as AMD leads sales
Seeking Alpha · 08/31 11:05
Weekly Report: what happened at FRNM last week (0824-0828)?
Weekly Report · 08/31 10:35
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
Benzinga · 08/28 14:22
SpaceX continues to be Cathie's biggest bet; trims RBLX, PLTR, and AMD
Seeking Alpha · 08/24 11:07
Weekly Report: what happened at FRNM last week (0817-0821)?
Weekly Report · 08/24 10:36
Freenome Price Target Announced at $21.00/Share by Guggenheim
Dow Jones · 08/20 13:21
Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
Benzinga · 08/20 13:10
Freenome initiated with a Buy at Guggenheim
TipRanks · 08/20 10:20
Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
Benzinga · 08/18 21:44
Freenome Price Target Announced at $17.00/Share by TD Cowen
Dow Jones · 08/18 14:27
TD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
Benzinga · 08/18 14:17
Freenome initiated with a Buy at TD Cowen
TipRanks · 08/18 09:45
Freenome Price Target Announced at $17.00/Share by Jefferies
Dow Jones · 08/17 12:09
Jefferies Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
Benzinga · 08/17 12:00
Weekly Report: what happened at FRNM last week (0810-0814)?
Weekly Report · 08/17 10:37
Freenome Price Target Announced at $17.00/Share by BTIG
Dow Jones · 08/17 10:11
BTIG Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
Benzinga · 08/17 10:01
Freenome initiated with a Buy at BTIG
TipRanks · 08/17 09:55
More
Webull provides a variety of real-time FRNM stock news. You can receive the latest news about Freenome, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About FRNM
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.